Pharmacotherapy for regional musculoskeletal pain

Best Practice and Research: Clinical Rheumatology

Volumn 17, Issue 1, 2003, Pages 137-150

  Kvien, Tore K ^a   Viktil, Kirsten ^b  

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b Pharmaceutical Services   (Norway)

Author keywords

COX 2 selective non steroidal anti inflammatory drugs; Non opioid analgesics; Non steroidal anti inflammatory drugs; Opioid analgesics; Randomized clinical trials; Regional musculoskeletal pain; Systematic reviews; Topical non steroidal anti inflammatory drugs

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; CARISOPRODOL; CELECOXIB; CODEINE; CORTICOSTEROID DERIVATIVE; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DEXTROPROPOXYPHENE; DICLOFENAC; ETORICOXIB; GLUCOCORTICOID; HYDROCODONE; IBUPROFEN; KETOBEMIDONE; MISOPROSTOL; MORPHINE; MUSCLE RELAXANT AGENT; NABUMETONE; NAPROXEN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; PARACETAMOL; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALDECOXIB; ARTHROTEC; CHLORZOXAZONE; CYCLOBENZAPRINE; CYCLOOXYGENASE 2; METAXALONE; METHOCARBAMOL; OPIATE; ORPHENADRINE CITRATE;

BONE PAIN; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC PAIN; CLINICAL PRACTICE; CLINICAL TRIAL; COCHRANE LIBRARY; CONSTIPATION; DISEASE CLASSIFICATION; DRUG ABSORPTION; DRUG ABUSE; DRUG COST; DRUG DEPENDENCE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; EUPHORIA; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; KIDNEY DYSFUNCTION; MAXIMUM PERMISSIBLE DOSE; METHODOLOGY; MONOTHERAPY; MYALGIA; OSTEOARTHRITIS; PHOTODERMATOSIS; PHOTOTOXICITY; PRIORITY JOURNAL; REVIEW; SHOULDER PAIN; SIDE EFFECT; SKELETAL MUSCLE; SYSTEMIC THERAPY; TOOTH PAIN; ULCER; VERTIGO; ANALGESIA; DIZZINESS; DROWSINESS; DRUG SAFETY; FIBROMYALGIA; LOW BACK PAIN; NEUROPATHIC PAIN; SYSTEMATIC REVIEW; TENDINITIS;

EID: 0037237373     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6942(02)00102-X     Document Type: Review

References (82)

1. Bellamy N, Kirwan J, Boers M et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. Journal of Rheumatology 1997; 24: 799-802.
2. Bombardier C, Hayden J & Beaton DE. Minimal clinically important difference. Low back pain: Outcome measures. Journal of Rheumatology 2001; 28: 431-438.
3. Towheed TE & Hochberg MC. A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the knee, with an emphasis on trial methodology. Seminars in Arthritis and Rheumatism 1997; 26: 755-770.
4. Towheed T, Shea B, Wells G & Hochberg M. Analgesia and non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the hip. Cochrane Database Systematic Reviews 2000; 2: CD000517
5. Watson MC, Brookes ST, Kirwan JR & Faulkner A. Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee. Cochrane Database Systematic Reviews 2000; 2: CD000142
6. Green S, Buchbinder R, Glazier R & Forbes A. Interventions for shoulder pain. Cochrane Database Systematic Reviews 2000; 2: CD001156.
7. Green S, Buchbinder R, Barnsley L et al. Non-steroidal anti-inflammatory drugs (NSAIDs) for treating lateral elbow pain in adults. Cochrane Database Systematic Reviews 2002; 2: CD003686
8. McLauchlan GJ & Handoll HH. Interventions for treating acute and chronic Achilles tendinitis. Cochrane Database Systematic Reviews 2001; 2: CD000232
9. Van Tulder MW, Scholten RJ, Koes BW & Deyo RA. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Systematic Reviews 2000; 2: CD000396
10. Amadio P & Cummings DM. Evaluation of acetaminophen in the management of osteoarthritis of the knee. Current Therapeutic Research, Clinical and Experimental 1983; 34: 59-65.
11. Eccles M, Freemantle N & Mason J. North of England evidence based guideline development project: Summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. The North of England non-steroidal anti-inflammatory drug guideline development group. British Medical Journal 1998; 317: 526-530.
12. Pendleton A, Arden N, Dougados M et al. EULAR recommendations for the management of knee osteoarthritis: Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Annals of the Rheumatic Diseases 2000; 59: 936-944.
13. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis and Rheumatism 2000; 43: 1905-1915.
14. Geba GP, Weaver AL, Polis AB et al. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: A randomized trial. Journal of the American Medical Association 2002; 287: 64-71.
15. Pincus T, Koch GG, Sokka T et al. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis and Rheumatism 2001; 44: 1587-1598.
16. Wolfe F, Zhao S & Lane N. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: A survey of 1799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis and Rheumatism 2000; 43: 378-385.
17. Courtney P & Doherty M. Key questions concerning paracetamol and NSAIDs for osteoarthritis. Annals of the Rheumatic Diseases 2002; 61: 767-773.
18. Chang DJ, Fricke JR, Bird SR et al. Rofecoxib versus codeine/acetaminophen in postoperative dental pain: A double-blind, randomized, placebo- and active comparator-controlled clinical trial. Clinical Therapeutics 2001; 23: 1446-1455.
19. Kjaersgaard-Andersen P, Nafei A, Skov O et al. Codeine plus paracetamol versus paracetamol in longer-term treatment of chronic pain due to osteoarthritis of the hip. A randomised, double-blind, multi-centre study. Pain 1990; 43: 309-318.
20. Li Wan PA & Zhang WY. Systematic overview of co-proxamol to assess analgesic effects of addition of dextropropoxyphene to paracetamol. British Medicine Journal 1997; 315: 1565-1571.
21. Roth SH. Efficacy and safety of tramadol HCl in breakthrough musculoskeletal pain attributed to osteoarthritis. Journal of Rheumatology 1998; 25: 1358-1363.
22. Turturro MA, Paris PM & Larkin GL. Tramadol versus hydrocodone-acetaminophen in acute musculoskeletal pain: A randomized, double-blind clinical trial. Annals of Emergency Medicine 1998; 32: 139-143.
23. Sunshine A. New clinical experience with tramadol. Drugs 1994; 47(supplement I):8-18.
24. Jensen EM & Ginsberg F. Tramadol versus dextropropoxyphene in the treatment of osteoarthritis. A short term double-blind study. Drug Investigation 1994; 8: 211-218.
25. Silverfield JC, Kamin M, Wu SC & Rosenthal N. Tramadol/acetaminophen combination tablets for the treatment of osteoarthritis flare pain: A multicenter, outpatient, randomized, double-blind, placebo-controlled, parallel-group, add-on study. Clinical Therapeutics 2002; 24: 282-297.
26. Schnitzer TJ, Gray WL, Paster RZ & Kamin M. Efficacy of tramadol in treatment of chronic low back pain. Journal of Rheumatology 2000; 27: 772-778.
27. Cicero TJ, Adams EH, Geller A et al. A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States. Drug and Alcohol Dependence 1999; 57: 7-22.
28. Roth SH, Fleischmann RM, Burch FX et al. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: Placebo-controlled trial and long-term evaluation. Archives of Internal Medicine 2000; 160: 853-860.
29. Hale ME, Fleischmann R, Salzman R et al. Efficacy and safety of controlled-release versus immediate-release oxycodone: Randomized, double-blind evaluation in patients with chronic back pain. Clinical Journal of Pain 1999; 26: 862-869.
30. Caldwell JR, Hale ME, Boyd RE et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: A double blind, randomized, multicenter, placebo controlled trial. Journal of Rheumatology 1999; 26: 862-869.
31. Turturro MA, Paris PM, Yealy DM & Menegazzi JJ. Hydrocodone versus codeine in acute musculoskeletal pain. Annals of Emergency Medicine 1991; 20: 1100-1103.
32. Gimbel JS, Brugger A, Zhao W et al. Efficacy and tolerability of celecoxib versus hydrocodone/acetaminophen in the treatment of pain after ambulatory orthopedic surgery in adults. Clinical Therapeutics 2001; 23: 228-241.
33. Linton SJ. A review of psychological risk factors in back and neck pain. Spine 2000; 25: 1148-1156.
34. Crawford F, Atkins D & Edwards J. Interventions for treating plantar heel pain. 2000; 3: CD000416
35. Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353: 307-314.
36. Riendeau D, Percival MD, Brideau C et al. Etoricoxib (MK-0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. Journal of Pharmacology and Experimental Therapeutics 2001; 296: 558-566.
37. Watson DJ, Harper SE, Zhao PL et al. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Archives of Internal Medicine 2000; 160: 2998-3003.
38. Hawkey CJ. NSAID toxicity: Where are we and how do we go forward? Journal of Rheumatology 2002; 29: 650-652.
39. Van Hecken A, Schwartz JI, Depre M et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. Journal of Clinical Pharmacology 2000; 40: 1109-1120.
40. Day R, Morrison B, Luza A et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. Archives of Internal Medicine 2000; 160: 1781-1787.
41. Ehrich EW, Bolognese JA, Watson DJ & Kong SX. Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis. The American Journal of Managed Care 2001; 7: 609-616.
42. Detora LM, Krupa D, Bolognese J et al. Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors. Journal of Rheumatology 2001; 28: 2494-2503.
43. Truitt KE, Sperling RS, Ettinger WH Jr et al. A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. Aging (Milan) 2001; 13: 112-121.
44. Zhao SZ, McMillen JI, Markenson JA et al. Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib. Pharmacotherapy 1999; 19: 1269-1278.
45. Bensen WG, Fiechtner JJ, McMillen JI et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial. Mayo Clinic Proceedings 1999; 74: 1095-1105.
46. McKenna F, Borenstein D, Wendt H et al. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scandinavian Journal of Rheumatology 2001; 30: 11-18.
47. Williams GW, Hubbard RC, Yu SS et al. Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee. Clinical Therapeutics 2001; 23: 213-227.
48. Leung AT, Malmstrom K, Gallacher AE et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized double-blind, placebo and active-comparator controlled 12-week efficacy trial. Current Medical Research and Opinion 2002; 18: 49-58.
49. Makarowski W, Zhao WW, Bevirt T & Recker DP. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: A randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis and Cartilage 2002; 10: 290-296.
50. Cannon GW & Breedveld FC. Efficacy of cyclooxygenase-2-specific inhibitors. American Journal of Medicine 2001; 110(supplement 3A): 6S-12S.
51. Lisse J, Espinoza L, Zhao SZ et al. Functional status and health-related quality of life of elderly osteoarthritic patients treated with celecoxib. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 2001; 56: M167-M175.
52. Morrison BW, Fricke J, Brown J et al. The optimal analgesic dose of rofecoxib: Overview of six randomized controlled trials. Journal of the American Dental Association 2000; 131: 1729-1737.
53. Reuben SS & Connelly NR. Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery. Anesthesia and Analgesia 2000; 91: 1221-1225.
54. Brater DC, Harris C, Redfern JS & Gertz BJ. Renal effects of COX-2-selective inhibitors. American Journal of Nephrology 2001; 21: 1-15.
55. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib long-term arthritis safety study. Journal of the American Medical Association 2000; 284: 1247-1255.
56. Juni P, Rutjes AW & Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? British Medical Journal 2002; 324: 1287-1288.
57. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. New England Journal of Medicine 2000; 343: 1520-1528.
58. Boers M. NSAIDS and selective COX-2 inhibitors: Competition between gastroprotection and cardioprotection. Lancet 2001; 357: 1222-1223.
59. FitzGerald GA & Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. New England Journal of Medicine 2001; 345: 433-442.
60. Konstam MA, Weir MR, Reicin A et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001; 104: 2280-2288.
61. White WB, Faich G, Whelton A et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. American Journal of Cardiology 2002; 89: 425-430.
62. Rahme E, Pilote L & LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Archives of Internal Medicine 2002; 162: 1111-1115.
63. Watson DJ, Rhodes T, Cai B & Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Archives of Internal Medicine 2002; 162: 1105-1110.
64. Solomon DH, Glynn RJ, Levin R & Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Archives of Internal Medicine 2002; 162: 1099-1104.
65. Dalen JE. Selective COX-2 inhibitors, NSAIDs, aspirin, and myocardial infarction. Archives of Internal Medicine 2002; 162: 1091-1092.
66. Wenkers BP & Lippold BC. Skin penetration of nonsteroidal antiinflammatory drugs out of a lipophilic vehicle: Influence of the viable epidermis. Journal of Pharmaceutical Science 1999; 88: 1326-1331.
67. Heyneman CA. Topical nonsteroidal antiinflammatory drugs for acute soft tissue injuries. Annals of Pharmacotherapy 1995; 29: 780-782.
68. Topical nonsteroidal antiinflammatory drugs: Allergic and photoallergic contact dermatitis and phototoxicity. Contact Dermatitis 1993; 29: 57-64.
69. Cutaneous reactions to topical NSAIDs. Prescrine International 2000; 9: 114-115.
70. Renal impairment due to topical NSAIDs. Prescrire International 2002; 11:86.
71. Moulin DE. Systemic drug treatment for chronic musculoskeletal pain. Clinical Journal of Pain 2001; 17(supplement 4): S86-S93.
72. O'Malley PG, Balden E, Tomkins G et al. Treatment of fibromyalgia with antidepressants: A meta-analysis. Journal of General Internal Medicine 2000; 15: 659-666.
73. Arnold LM, Keck PE Jr. & Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics 2000; 41: 104-113.
74. Fishbain D. Evidence-based data on pain relief with antidepressants. Annals of Medicine 2000; 32: 305-316.
75. Salerno SM, Browning R & Jackson JL. The effect of antidepressant treatment on chronic back pain: A meta-analysis. Archives of Internal Medicine 2002; 162: 19-24.
76. Waldman HJ. Centrally acting skeletal muscle relaxants and associated drugs. Journal of Pain and Symptom Management 1994; 9: 434-441.
77. Vaeroy H, Abrahamsen A, Forre O & Kass E. Treatment of fibromyalgia (fibrositis syndrome): A parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp) versus placebo. Clinical Rheumatology 1989; 8: 245-250.
78. Baratta RR. A double-blind comparative study of carisoprodol, propoxyphene, and placebo in the management of low back syndrome. Current Therapeutic Research, Clinical and Experimental 1976; 20: 233-240.
79. Gallardo F, Molgo J, Miyazaki C & Rossi E. Carisoprodol in the treatment of myofascial pain-dysfunction syndrome. Journal of Oral Surgery 1975; 33: 655-658.
80. Hindle TH III. Comparison of carisoprodol, butabarbital, and placebo in treatment of the low back syndrome. California Medicine 1972; 117: 7-11.
81. Curatolo M & Bogduk N. Pharmacologic pain treatment of musculoskeletal disorders: Current perspectives and future prospects. Clinical Journal of Pain 2001; 17: 25-32.
82. Reeves RR, Pinkofsky HB & Carter OS. Carisoprodol: A drug of continuing abuse. The Journal of the American Osteopathic Association 1997; 97: 723-724.